<DOC>
	<DOCNO>NCT01767389</DOCNO>
	<brief_summary>This study assess utilization pattern ( adherence , source index antidiabetic agent ( ADA ) treatment modification ) market glucagon-like peptide-1 ( GLP-1 ) receptor agonist ( exenatide liraglutide ) , dipeptidyl-peptidase-4 ( DPP-4 ) inhibitor ( sitagliptin , saxagliptin , linagliptin ) ADAs incidence rate acute pancreatitis among user GLP-1 receptor agonists user DPP-4 inhibitor , separately , comparison ADAs . The propose study help understand treatment utilization pattern incidence rate acute pancreatitis among user market GLP-1 receptor agonist . This study differ previous observational study include exenatide liraglutide follow-up time expect longer current study ( 2005 - 2011 ) . This study retrospective cohort study conduct Truven ( Thomson Reuters ) commercial health insurance database 2005-2011 .</brief_summary>
	<brief_title>Glucagon-like Peptide ( GLP ) Utilization Safety</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<mesh_term>Dipeptidyl-Peptidase IV Inhibitors</mesh_term>
	<criteria>Subjects age ≥ 18 ≤ 64 year index date continuous enrolment least 12 month Truven Subjects complete medical pharmacy benefit continuous enrolment health plan least 12 month index date ( preindex period ) . Subjects also least 1 claim T2D diagnosis identify use ICD9 cod 250.x0 250.x2 ( exclude 250.x1 and/or 250.x3 Type 1 diabetes 648.0x gestational diabetes ) For objective evaluate association GLP1 receptor agonist , DPP4 inhibitor acute pancreatitis compare association observe outcome use ADAs , subject evidence pancreatic disease ( ICD 9 code 577.xx ) preindex period ( 12 month index date ) exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>utilization</keyword>
	<keyword>acute pancreatitis</keyword>
	<keyword>Exenatide</keyword>
	<keyword>DPP-4 inhibitor</keyword>
	<keyword>liraglutide</keyword>
	<keyword>GLP-1 receptor agonist</keyword>
	<keyword>adherence</keyword>
</DOC>